Current pharmacotherapy of AD acts mainly on the cholinergic and glutamatergic systems, with the acetylcholinesterase (AChE) and/or butyrylcholinesterase (BChE) inhibitors donepezil [8], galantamine [9], rivastigmine [8], and memantine, an N-methyl-d-aspartate antagonist [8,10], being the only drugs clinically used, albeit with limited therapeutic success and benefit. The gene discussed is ACHE; the disease is Alzheimer disease.